Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma

Among patients with advanced melanoma, median overall survival was 72 months with nivolumab plus ipilimumab and was 37 months with nivolumab alone, as compared with 20 months with ipilimumab alone.

​   The New England Journal of Medicine: Search Results in Hematology/Oncology